Table of Contents
AMA Research are pleased to announce the publication of the 2nd Edition of the report 'Pharmaceutical and Biotechnology Construction Sector Report – UK 2014-2018 Analysis'. The report should be of particular interest to construction companies and their supply chains operating in the UK Life Sciences sector, and to suppliers of laboratory and allied products.
Key areas in the report:
• Review of the pharmaceutical, medical technology, medical and industrial biotechnology sectors – market size, key players and geographical areas of concentration.
• Overview of main manufacturing and R&D facilities in UK.
• Review of construction activity in the sector - key projects, pipelines, players etc.
• Analysis of Government resource and capital funding for science and research.
Areas of particular interest:
• Major contractors, consultants, architects and product suppliers involved in the pharmaceutical and biotechnology sectors.
• Capital Expenditure levels in the pharmaceutical/biotechnology market.
• Construction costs and issues in the design of pharmaceutical R&D/manufacturing facilities including legislation, regulatory requirements, containment and environmental issues, cleanroom and laboratory design.
• Profiles of top pharmaceutical/biotechnology companies operating in the UK - revenue, capital expenditure, key manufacturing & R&D facilities in UK, future strategy, expansion plans, forward pipelines etc.
• Forward pipeline of capital projects in the pharmaceutical sector between 2014-2018. Review of key projects together with announcements made by leading pharmaceutical companies and universities about future expansion and investment plans.
• Detailed analysis of pharmaceutical/biotech clusters and centres of excellence in the UK - the Oxford, Cambridge and London triangle houses the UK’s largest biomedical cluster, with over 350 pharma and biotech companies linked to universities and other organisations.
Leading pharmaceutical and biotechnology companies mentioned in the report include:
AstraZeneca, Abbott Laboratories, Abcam, ABS Laboratories, ACM Global Central Lab, Allergan, Bayer CropScience, Bells Healthcare, Calea (UK), Cancer Research Technology, Cantab Biopharmaceuticals, Carbogen Amcis, Cobra Biomanufacturing, Convergence Pharmaceuticals, Eli Lilly, GlaxoSmithKline, Huntingdon Life Sciences, Intercytex, Isis Innovation, Life Technologies, Lonza Biologics, MedImmune, Merck & Co, Mundipharma International, Norbrook Pharmaceuticals, Novartis UK, NuPharm Laboratories, Oxygen Healthcare, Pfizer, Pharmaserve Northwest, PsiOxus Therapeutics, Reading Scientific Services, Recipharm, Renovo, Roche, Sanofi Aventis, Sareum, Teva Pharmaceutical Industries, TPP Global Development, UCB Pharma, Unilever.
Leading construction companies and consultants mentioned in the report include:
ABB Group, AECOM, AMEC, Ardmac, Bassaire, BDP, Bilfinger SE, Cavendish Engineers, Clean Air Technologies, Clean Modules, Cleanroom Design & Construction, Cleanroom Solutions, ClearSphere, Enbloc Cleanrooms, Foster Wheeler, Jacobs Engineering, Kier Group, Laing O’Rourke, Lend Lease, M+W Group, Mach-Aire, Merit Merrell, Morgan Sindall, Nuvia, PM Group, Precision Cleanrooms, SDC, Shepherd Construction, Sheppard Robson, SISK Group, Validair, Wilson Mason.
Key areas covered in the report include:
OVERALL ‘ PHARMACEUTICAL’ MARKET
• Global Market - analysis of size by value 2009-16, historical trends and market characteristics.
• UK Pharmaceutical Market – by value 2011-16 – overview/ mix of key sectors – Pharmaceutical, Medical Technology, Medical Biotechnology, Industrial Biotechnology.
• Review of each key sector – key players, sector value, number of companies/staff, key locations, overview of development pipelines etc.
• Summary overview of Top 30+ companies in Pharmaceuticals / Biotechnology - major companies and geographic location of facilities in UK – Manufacturing, R&D, Packaging, Logistics.
• Geographic review – Oxford, Cambridge, London clusters. Other key regional areas - North West, Scotland, East England, South East etc – key players, future trends.
• R&D in UK – budgets, funding sources. Government Resource and Capital Funding for Science & Research 2011 – 2016. Research Councils (HEFCE, EPSRC, MRC etc). Key funding recipients. Overview of R&D – key players, locations, development plans.
• Top 20 companies in UK by R&D expenditure and by Drug Pipeline 2012/13.
• Top players – market shares. Company profiles - Key Operating & Financial Summary Data (Incl: Capital and R&D Expenditure, Locations, Pipelines, Future Strategy etc).
• Review of smaller players – pharmaceuticals / biotechnology – Capex, R&D, locations, developments etc.
• Universities – key links/collaborations with private sector, players (Top 20 with funding levels / sources). University/industry collaborations in the Pharmaceutical Sector – Partners, Funding, Project Areas etc.
• Spin-out companies - between 2006 and 2010 university spin-out companies floated on the stock market were worth around £3.5bn and over the over the past decade, university bioscience departments alone have generated over 200 spin-out companies – overview of key players.
• UK Science Parks - geographical spread, size / development plans, sectors, partners – Biocity, Liverpool, West of Scotland, York, Oxford, Cambridge etc.
• Capital Expenditure – 2001-2012 by Value – trends, background, drivers etc.
• Science & Research Projects - Forward Construction Pipeline 2012-2017 – Schemes, Description, Funding Source, Status, Start/Completion Dates, Capex etc.
• Other development announcements – plans – medium/long term, new opportunities etc.
• Construction costs – laboratories, cleanrooms, key guidelines.
• Leading Contractors – specialist cleanroom players (construction, supply and services).
• Key consultants / contractors – Pharmaceuticals, Biotechnology - profiles of 20+ players – sector characteristics, major strengths and weaknesses, key sectors and capabilities.The UK is the 9th largest pharmaceutical market in the world, and the sector makes a greater contribution to the UK economy than any other industrial sector – worth around £29bn - and generating an annual trade surplus of almost £3bn. The Industry is particularly important in terms of its research and development (R&D) contribution and the pharmaceutical sector alone accounts for more UK-based business R&D than any other manufacturing sector – around £4.2bn is spent on pharmaceutical R&D in the UK, almost 25% of the total industrial R&D spend.
Growth rates are now significantly slower than in previous years, due to slowing R&D pipelines, dwindling R&D and healthcare budgets, rising costs, impending ‘patent cliffs’, increased regulatory controls and increased pricing pressures. In addition, significant public spending cuts especially in the health sector and tighter NHS spending is forecast to impact negatively on the pharmaceutical market. However, industry revenue is forecast to grow by around 2% between now and 2018.
The top 10 global pharmaceutical companies account for around £24bn or 47.3% of total UK sector turnover. Many of the top global pharmaceutical companies have a considerable manufacturing and research presence in the UK. 12 out of the top 20 global pharmaceutical companies account for a total of 55 UK sites.
Many of the UK’s biotech firms are located around Oxford, Cambridge and in Scotland. Known as ‘The Golden Triangle’ the centres of London, Cambridge, Oxford and Stevenage house the UK’s largest biomedical cluster in the UK. London and Cambridge are home to at least 60% of the UK’s life science industry base, with biotechnology R&D accounting for approximately 22% of the companies. Clusters of pharmaceutical companies are also found in areas close to universities. The North West, in particular, is home to ‘Big Pharma’, with several global pharmaceutical companies operating a facility in the region.
Capital expenditure by pharmaceutical companies in the UK has been in decline, with R&D capital expenditure falling by around £359m from £496m in 2002 to just £137m in 2012 and pharmaceutical manufacturing capital expenditure declining from a peak of nearly £1bn in 2001 to just £422m in 2012. For pharmaceutical manufacturing companies, the greatest barrier to capital investment in the UK over the last few years has been the lack of financial incentive to locate new manufacturing (or retain existing manufacturing plants) in the country.
However, the Government has also announced a forward pipeline of over £200m worth of capital projects in the pharmaceutical and biotechnology sectors between now and 2018. In addition to these confirmed capital projects, a number of expansion plans have been announced by leading pharmaceutical companies, which should be of interest to construction companies and their supply chains operating in the pharmaceutical sector and to suppliers of laboratory and allied products.
Increasing specialisation within the pharmaceutical industry has brought about varied opportunities for construction engineers and contractors to design and develop R&D facilities, pharmaceutical production processes, and assembly of drug delivery devices/systems, construction and maintenance of highly specialized production facilities, associated service/support facilities and continuous improvement of process operations.
Andrew Hartley, Director of AMA Research said “Current design and construction trends are moving away from ‘bespoke’ buildings to flexible and mobile laboratories and cleanrooms requiring less time to design and build and incorporating modern methods of construction. The demand for mobile or modular cleanrooms is increasing driven by industry cutbacks which have forced many pharmaceutical companies to rethink their business and manufacturing operations.”
While the performance of the global pharmaceutical market is now more positive in 2014 than in 2009, the fundamental problems of patent expiration and funding pressures still exist and will slow market increases to single-digit growth over the next few years and drive a shift towards generic drug equivalents. The pharmaceutical industry is facing a number of pressures which are set to limit sales, including price cuts and cost containment issues, growing regulatory pressure and major US and UK healthcare reforms. Cost-savings facilitated by mergers and acquisitions, geographic expansion into emerging markets and diversification into new areas such as consumer health are also set to drive the market going forward.
Get Industry Insights. Simply.
Talk to Veronica
+1 718 514 2762
PharmaPoint: Systemic Lupus Erythematosus and Lupus Nephritis - Global Drug Forecast and Market Analysis to 2025 Summary Systemic Lupus Erythematosus (SLE) is a systemic inflammatory autoimmune disease ...
PharmaPoint: Ulcerative Colitis - Global Drug Forecast and Market Analysis to 2025 Summary Ulcerative Colitis (UC) is a type of chronic IBD that causes inflammation and ulcers in the innermost lining of ...
PharmaFocus: Tauopathies - Global Market Analysis Summary Tauopathies are a class of more than 20 neurodegenerative diseases characterized by tau protein aggregation in the brain. There are currently no ...